GAITHERSBURG, Md., July 19 /PRNewswire/ -- Panacea Pharmaceuticals, Inc. today announced the appointments of Steven A. Fuller, Ph.D. as Vice President, Product Development, and Billie Jo Wood as Director, Clinical Laboratory Services. Dr. Fuller will direct preclinical product development, validation, process development, and manufacturing for the Company’s therapeutic and diagnostic products, in collaboration with staff in regulatory affairs and clinical development. Ms. Wood will assume responsibility for managing Panacea Laboratories, a division of Panacea Pharmaceuticals, including testing of patient samples, assuring adherence to regulatory requirements, and marketing the availability of the Company’s diagnostic tests.
“We are very pleased to add Steve and Billie Jo to the team at Panacea”, commented Stephen N. Keith, MD, MSPH, President and Chief Operating Officer at Panacea Pharmaceuticals. “Steve brings a wealth of experience in the development and manufacturing of a range of therapeutic and diagnostic products. And Billie Jo has considerable experience managing a clinical laboratory at one of the leading academic medical centers. Panacea is continuing to strengthen its senior management team as we aggressively pursue our therapeutic and diagnostic product development efforts.”
Dr. Fuller has over 23 years of experience in the pharmaceutical and biotechnology industries working on a range of therapeutic and diagnostic products. Most recently Dr. Fuller served as Vice President, Product and Process Development at Nabi Biopharmaceuticals, Inc. While at Nabi, he held positions of increasing responsibility including Senior Director, Product Development and Product Development Director. At ADI Diagnostics, Dr. Fuller was a Senior Research Scientist, Program Manager and Director of Operations; ADI Diagnostics is a diagnostics manufacturer and distributor specializing in cancer and infectious disease assays. He is an author of numerous peer- reviewed publications and one patent. Dr. Fuller received his B.S. degree in Biology from Wheaton College and his Ph.D. in genetics from Michigan State University. He is a member of the American Society for Microbiology and the American Association for Laboratory Animal Science.
Prior to joining Panacea, Ms. Wood worked as a Laboratory Coordinator at the Johns Hopkins University Medical Center, supervising technicians and providing staff consultation to ensure accurate performance of tests and reporting test results in compliance with the Clinical Laboratory Improvement Amendments of 1988 and the Joint Commission on Accreditation of Healthcare Organizations regulations. Ms. Wood has experience utilizing polymerase chain reaction, gel electrophoresis, cell culture, microimmuno-fluorescence, and nucleic acid amplification. She received her Bachelor of Science in Biology from York College of Pennsylvania, and a Masters of Science in Biotechnology and a MBA from Johns Hopkins.
About Panacea Pharmaceuticals, Inc.
Panacea Pharmaceuticals, Inc. is a privately-held biopharmaceutical company focused on the development and commercialization of therapeutics and diagnostics for diseases with substantial, unmet clinical needs. The Company’s product development strategy is based on novel therapeutic agents and approaches for cancer treatment, as well as acute and chronic neurodegenerative conditions, such as hypoxia-induced neurological insult, Parkinson’s Disease, and Alzheimer’s disease. Panacea has an extensive patent portfolio covering its neurodegenerative and oncology technologies.
More information about the Company is available at http://www.PanaceaPharma.com.
Except for historical information presented in this press release, matters discussed herein may constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward- looking statements are based on the opinions and estimates of management only as of the date of this release and are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance, or achievements expressed or implied by such statements. Factors that might cause such a difference include, but are not limited to, uncertainties related to our access to capital, the progress, costs, and results of any clinical trials undertaken by us, progress of our research and development projects, and uncertainties related to whether our product candidates would ultimately achieve commercial success. We do not undertake any obligation to update publicly any forward-looking statement, whether as a result of new information, future events, or otherwise unless required by law.
Panacea Pharmaceuticals, Inc.
CONTACT: Stephen N. Keith, MD, MSPH, President & COO of PanaceaPharmaceuticals, Inc., +1-240-243-8000, or fax +1-240-465-0450,skeith@panaceapharma.com
Web site: http://www.panaceapharma.com//
